Scandinavian ChemoTech

A key factor behind this success is the increasing recognition of the clinical and financial benefits of TSE treatments. Customer satisfaction remains a cornerstone of our growth, with clients expressing appreciation for both the effectiveness of our technology and the high level of service we provide.

"To start the year with such a strong first quarter is truly encouraging and sets a positive tone for the months ahead," says Ann Ohlsson, Head of Finance at Scandinavian ChemoTech and VQ Animal Care. "Even with this solid performance, we see our pipeline expanding-not only in terms of business opportunities but also in the speed at which they materialize. Consistently increasing our revenues quarter by quarter strengthens our confidence in our forecasts and long-term potential."

With this strong start to 2025 and an accelerating demand for our innovative veterinary solutions, Animal Care is well-positioned for continued success. The company remains focused on sustainable growth, bringing the group closer to its first profitable quarter sooner than anticipated.